APELLIS PHARMACT.DL-0001 (1JK F) stock market data APIs

€26.62 -0.45(-1.7%)
as of February 11, 2025

APELLIS PHARMACT.DL-0001 Financial Data Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Prev. Close 26.77
Open 26.62
High 27.44
Low 26.64
52 wk Range 23.68-65.5
Market Cap 3 527 M
Shares Outstanding 124 M
Revenue 715 M
EPS -2.72
Beta 0.867

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get APELLIS PHARMACT.DL-0001 data using free add-ons & libraries


Get APELLIS PHARMACT.DL-0001 Fundamental Data

APELLIS PHARMACT.DL-0001 Fundamental data includes:

  • Net Revenue: 715 M
  • EBITDA: -221 507 008
  • Earnings Per Share: -1
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get APELLIS PHARMACT.DL-0001 Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2021-06-30
  • EPS/Forecast: -1.69
GET THE PACKAGE

Get APELLIS PHARMACT.DL-0001 End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

APELLIS PHARMACT.DL-0001 News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat